MétaCan
Menu
← Back to cohort
Record W1973115670 · doi:10.1016/j.jalz.2011.05.390

P1‐111: Development of ultra‐sensitive assay for detection of aggregated beta amyloid in human CSF

2011· article· en· W1973115670 on OpenAlexaff
Louise A. Scrocchi, Kaj Blennow, Henrik Zetterberg, Elizabeth Karaskov, Vivian Lee, Hui Chen, Marni D. Uger, Neil R. Cashman, Marty T. Lehto

Bibliographic record

VenueAlzheimer s & Dementia · 2011
Typearticle
Languageen
FieldMedicine
TopicAlzheimer's disease research and treatments
Canadian institutionsAmorfix (Canada)
Fundersnot available
KeywordsEpitopeBiomarkerImmunoassayCerebrospinal fluidMonoclonal antibodyAmyloid betaMedicineAntibodyChemistryDiseaseImmunologyInternal medicineBiochemistry

Abstract

fetched live from OpenAlex

More than 35 million people worldwide have Alzheimer's disease (AD). A major stumbling block to treatment is the absence of robust biomarkers for early detection and monitoring during clinical trials. There is a need for more sensitive and reliable diagnostics to assess the levels of biomarkers in order for current therapeutics to be effective, and for enrollment into clinical trials. Amorfix Life Sciences has developed the EP-AD Diagnostic CSF Test as a quantitative and ultra-sensitive biomarker assay for detection of oligomeric Aβ in human CSF. The EP-AD Diagnostic CSF Test makes use of two methods to isolate and detect oligomeric Aβ while minimizing the signal from monomeric Aβ in CSF. Samples were treated using Epitope Protection (EP) technology to chemically modify epitopes present on the surface of monomeric Ab and prevent antibody recognition. This was followed by affinity-based enrichment of oligomeric Aβ. Oligomeric Aβ was eluted from the enrichment matrix with a disaggregant, and detected using an ultra-sensitive dual bead based immunoassay. Conditions were optimized until the signal from monomeric Ab measured in untreated control CSF (S/N > 600) was reduced below background (S/N < 2.0). Following Epitope Protection and enrichment it was possible to detect a 1/8,000 dilution of a 10% AD brain homogenate spiked into control CSF. Proof-of-concept validation using clinical CSF samples was performed with a blinded panel of twelve (12) samples (6 AD, 6 controls). The EP-AD Test correctly identified 5/6 AD (83% sensitivity) and 5/6 control samples (83% specificity). A second panel of twenty three (23) samples was tested with the following 7/11 AD CSF correctly identified (64% sensitivity) and 9/12 control CSF correctly identified (75% specificity). We have developed methods to minimize the signal from monomeric Aβ, and for specific enrichment of oligomeric Aβ from human CSF. Proof-of-concept validation suggests that this assay shows promise as a potential diagnostic biomarker assay. While the preliminary data is encouraging, further studies with a larger sample set will be required to validate the Amorfix EP-AD Diagnostic CSF Test and evaluate its potential for distinguishing AD from healthy controls, mild cognitive impairment (MCI), and other dementia conditions

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.002
metaresearch head score (Gemma)0.002
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.002
Threshold uncertainty score0.010

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0020.002
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0010.001
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0020.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.053
GPT teacher head0.308
Teacher spread0.255 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2011
Admission routes1
Has abstractyes

Explore more

Same venueAlzheimer s & Dementia→Same topicAlzheimer's disease research and treatments→French-language works237,207→